Navigation Links
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Date:5/28/2009

ated Prograf or cyclosporine concentrations, dosing with the other drug usually should be further delayed.

Use of Prograf with sirolimus in heart transplant patients in a US study was associated with increased risk of wound healing complications, renal function impairment, and insulin-dependent post-transplant diabetes, and is not recommended.

Mild to severe hyperkalemia was reported in 31% of kidney transplant recipients, in 45% and 13% of liver transplant recipients in the US and European randomized trials, respectively, and in 8% of heart transplant recipients in a European randomized trial, and may require treatment. Serum potassium levels should be monitored and potassium-sparing diuretics should not be used during Prograf therapy (see PRECAUTIONS).

Neurotoxicity, including tremor, headache, and other changes in motor function, mental status, and sensory function, was reported in approximately 55% of liver transplant recipients in the two randomized studies. Tremor occurred more often in Prograf-treated kidney transplant (54%) and heart transplant patients (15%) compared with cyclosporine-treated patients. Seizures have occurred in adult and pediatric patients receiving Prograf. Coma and delirium also have been associated with high plasma concentrations of tacrolimus.

In post marketing experience, patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If PRES is suspected or diagnosed, immediate reduction of immunosuppression is advised. Activation of latent viral infections, including BK virus-associated nephropathy and JC virus-associated progressive multifocal leukoencephalopathy (PML), has also been reported. These viral infections may lead to serious, including fatal, outcomes.

The principal adverse reactions of Prograf include tremor, headache, hypertension, gastrointestinal disturbance, abnormal ren
'/>"/>

SOURCE Astellas
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
2. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
3. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
4. CV Therapeutics Statement on Unsolicited Proposal From Astellas
5. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
6. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
7. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
8. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
9. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
10. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
11. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ... East & Africa Biomedical Sensors Market - Growth, Trends ... The Middle East ... billion by 2018 at a CAGR of 3.26% over ... bring Biomedical sensors that are adaptable to the genetic ...
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... lead candidate, PPL-003, to an Investigational New Drug (IND) ... and uveitis.  PPL recently completed a study in a ... solution achieved highly significant efficacy and a more rapid ...
(Date:8/31/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... scientific review has identified high value opportunities for ... patient need. Novogen is moving as quickly as ... entering into Phase 1 clinical trials with our ... Officer, Iain Ross , said that following ...
(Date:8/31/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2015 ... on the discovery and development of novel cancer immunotherapies, ... , M.D., Ph.D., as Chief Executive Officer and ... Drs. Wong and Ho join an experienced management team ... company: Jordan Fridman , Ph.D., Chief Scientific Officer; ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... ... to provide online tutorial suite, Quick Reference Cards, and other training and outreach programs. ... Seattle, WA (PRWEB) April 13, ... has partnered with OpenHelixTM to provide comprehensive training and outreach programs for its ...
... Researchers at Uppsala University have developed a new method ... Hopes are strong that the method represents an important ... new diagnostic tests. The new method, which ... should enable studies of the effects of genetic variation ...
... ... Deliver Results Faster with New User Interface and Improved Support for Complex Experiments. ... (PRWEB) April 12, ... life science research, today announced Genedata Screener® 8. Developed over the past year to ...
Cached Biology Technology:RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials 2RCSB PDB Teams with OpenHelix to Announce Free Tutorial and Training Materials 3Mutations directly identifiable in active genes 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 3Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 4
(Date:8/12/2015)... As the digital payment services ... advanced biometrics technology is accelerating beyond expectations.  While the ... using their credit cards, the digital currency, mobile payment ... services led by companies in the space such as ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... of Marine Geology and Geophysics at the University of Miami ... off the fall semester with the inauguration of sophisticated equipment ... manner. Stable isotopes are used by biogeochemists to help ... using small organisms found in sediment cores. ...
... October issue of Infection Control and Hospital Epidemiology, ... uses a famous case of international intrigue and murder to ... while treating patients with radiation poisoning. The study ... Litvinenko, the Russian dissident and former KGB operative who died ...
... delivered directly to a particularly stubborn type of breast ... of recurrence and helps increase the effectiveness of some ... MD Anderson Cancer Center reported in the Sept. 13 ... and mouse studies, scientists found the gene mutation BikDD ...
Cached Biology News:'Clumps' of opportunities for cutting edge science 2Polonium poisoning case sheds light on infection control practices 2Gene therapy kills breast cancer stem cells, boosts chemotherapy 2Gene therapy kills breast cancer stem cells, boosts chemotherapy 3
... Kits are designed for ultra-sensitive detection ... or PVDF membranes. Since all necessary ... primary antibodies), the WesternBreeze Kits save ... protocol and getting your final results. ...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
... Adhesion Molecule The L1CAM ... involved in three distinct conditions: 1) HSAS ... MASA (mental retardation, aphasia, shuffling gait, adductus ... Immunogen: Homogenous suspension of ...
...
Biology Products: